For research use only
| Product Infomation | |
| Product Name | GSK3179106 |
|---|---|
| CAS No. | 1627856-64-7 |
| Molecular Weight | 467.41 |
| Formula | C₂₂H₂₁F₄N₃O₄ |
| SMILES | O=C(NC1=NOC(C(C)(C)C(F)(F)F)=C1)CC2=CC=C(C(C(OCC)=C3)=CNC3=O)C=C2F |
| Stock status | Get quote |
Online consultation: 
Product description
| Description | GSK3179106 is an orally active and selective RET kinase inhibitor with IC50s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity[1]. | |
| IC50 & Target | ________________________________________________________________________________________ IC50: 0.4 nM (human RET), 0.2 nM (rat RET)[1] | |
| In Vitro | _________________________________________________________________________________________ GSK3179106 (10 nM-100 µM; 8 days for TT cells, 3 days for SK-N-AS and A549 cells) inhibits the proliferation of the RET-dependent TT cell line with a mean IC50 value of 25.5 nM however has no effect on the proliferation of the RET-independent SK-NAS and A549 cell lines (mean IC50>10 µM and IC30>17 µM, respectively)[1]. | |
| Powder | -20°C | 3 years |
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month | |
Peferences:
[1]. Russell JP, et al. Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. J Pharmacol Exp Ther. 2019 Feb;368(2):299-307.
